Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD8186 + Docetaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD8186 | AZD-8186|AZD 8186 | PIK3CB inhibitor 8 PIK3CD inhibitor 27 | AZD8186 selectively inhibits the activity of PI3Kbeta (PIK3CB) and delta (PIK3CD) in the PI3K/Akt/mTOR signaling pathway, which may result in decreased tumor cell proliferation (PMID: 25514658, PMID: 32194423). | |
| Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN inact mut | Advanced Solid Tumor | no benefit | AZD8186 + Docetaxel | Phase I | Actionable | In a Phase I trial, treatment with the combination of AZD8186 and Taxotere (docetaxel) was generally well tolerated but demonstrated limited efficacy with an overall response rate of 5.6% (1/18), clinical benefit rate of 22.2% (4/18), and median progression-free survival of 3 months in patients with advanced solid tumors harboring PTEN inactivating mutations (n=21) or PIK3CB activating mutations (n=3) (PMID: 40939237; NCT03218826). | 40939237 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03218826 | Phase I | AZD8186 + Docetaxel | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |